BR112014002986A2 - composição sob a forma de uma solução injetável, e formulação de dose única - Google Patents

composição sob a forma de uma solução injetável, e formulação de dose única

Info

Publication number
BR112014002986A2
BR112014002986A2 BR112014002986A BR112014002986A BR112014002986A2 BR 112014002986 A2 BR112014002986 A2 BR 112014002986A2 BR 112014002986 A BR112014002986 A BR 112014002986A BR 112014002986 A BR112014002986 A BR 112014002986A BR 112014002986 A2 BR112014002986 A2 BR 112014002986A2
Authority
BR
Brazil
Prior art keywords
injection
composition
solution
single dose
dose formulation
Prior art date
Application number
BR112014002986A
Other languages
English (en)
Inventor
Geissler Alexandre
GéRARD SOULA
Olivier Soula
Jeff Tonnar
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1157291A external-priority patent/FR2978918B1/fr
Priority claimed from FR1162445A external-priority patent/FR2984749A1/fr
Application filed by Adocia filed Critical Adocia
Publication of BR112014002986A2 publication Critical patent/BR112014002986A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014002986A 2011-08-10 2012-08-09 composição sob a forma de uma solução injetável, e formulação de dose única BR112014002986A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161522031P 2011-08-10 2011-08-10
FR1157291A FR2978918B1 (fr) 2011-08-10 2011-08-10 Solution injectable a ph7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5
US201161579966P 2011-12-23 2011-12-23
FR1162445A FR2984749A1 (fr) 2011-12-23 2011-12-23 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
PCT/FR2012/051880 WO2013021143A1 (fr) 2011-08-10 2012-08-09 Solution injectable d'au moins une insuline basale

Publications (1)

Publication Number Publication Date
BR112014002986A2 true BR112014002986A2 (pt) 2017-06-13

Family

ID=47667929

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002986A BR112014002986A2 (pt) 2011-08-10 2012-08-09 composição sob a forma de uma solução injetável, e formulação de dose única

Country Status (14)

Country Link
US (3) US9089476B2 (pt)
EP (2) EP3053590A1 (pt)
JP (1) JP5950477B2 (pt)
KR (1) KR101810055B1 (pt)
CN (1) CN103889442B (pt)
AU (1) AU2012293463B2 (pt)
BR (1) BR112014002986A2 (pt)
CA (1) CA2843586A1 (pt)
DK (1) DK2741765T3 (pt)
IL (1) IL230611A (pt)
MX (1) MX2014001190A (pt)
RU (1) RU2578460C2 (pt)
WO (1) WO2013021143A1 (pt)
ZA (1) ZA201400773B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843586A1 (fr) 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
US9198971B2 (en) 2012-01-09 2015-12-01 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
FR3001895B1 (fr) * 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
SG11201601477VA (en) 2013-09-30 2016-04-28 Wockhardt Ltd Pharmaceutical composition
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
FR3020952B1 (fr) * 2014-05-14 2017-09-08 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN107949374B (zh) * 2015-09-04 2022-04-08 莱迪杜德制药公司 稳定的胰高血糖素溶液
WO2017084696A1 (fr) * 2015-11-16 2017-05-26 Adocia Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
EP3419649A1 (en) * 2016-02-25 2019-01-02 Wockhardt Limited Pharmaceutical composition of insulin glargine and amino acids
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
FR3052072A1 (fr) 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN110366424B (zh) * 2016-12-27 2024-05-24 阿道恰公司 包含胰淀素、胰淀素受体激动剂或胰淀素类似物和共聚氨基酸的可注射水溶液形式的组合物
FR3070264A1 (fr) 2017-08-24 2019-03-01 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) 2018-06-29 2020-10-02 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110625A1 (fr) 2017-12-06 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN111727049A (zh) 2017-12-07 2020-09-29 阿道恰公司 Ph 7的包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的可注射溶液
MX2020005913A (es) 2017-12-07 2020-10-19 Adocia Solución inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoácido con cargas de carboxilato y radicales hidrofóbicos.
CA3084689A1 (fr) 2017-12-07 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019193353A1 (en) * 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
US20210113763A1 (en) * 2018-04-04 2021-04-22 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
KR20200139700A (ko) * 2018-04-04 2020-12-14 아레콜 리미티드 인슐린 화합물의 전달을 위한 의료용 주입 펌프 시스템
MX2021000099A (es) * 2018-06-29 2021-03-25 Basf Se Sales de esteramina.
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2387201A (en) 1942-01-12 1945-10-16 Bonneville Ltd Mono-acyl ethylene diamines
EP0160103B1 (en) 1983-10-26 1990-06-20 Kanebo, Ltd. Proteinous emulsifier, process for its preparation, and emulsified cosmetic preparation containing same
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US6599498B1 (en) 1999-04-09 2003-07-29 Advanced Magnetics, Inc. Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
IL140844A0 (en) 2001-01-10 2002-02-10 Polygene Ltd Cationic polysaccharide compositions
KR20040070237A (ko) 2001-12-20 2004-08-06 일라이 릴리 앤드 캄파니 연장된 작용 시간을 갖는 인슐린 분자
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DE60321816D1 (de) 2002-12-04 2008-08-07 Flamel Tech Sa Polyaminosäuren, funktionalisiert durch mindestens eine (oligo-)aminosäure und ihre, insbesondere therapeutische, anwendung
EP1620465A2 (en) 2003-04-29 2006-02-01 Eli Lilly And Company Insulin analogs having protracted time action
KR101243648B1 (ko) * 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
FR2862536B1 (fr) 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2873040B1 (fr) 2004-07-19 2007-11-30 Flamel Technologies Sa Formulation colloidale d'insuline longue action et sa preparation
US20090011976A1 (en) 2004-11-12 2009-01-08 Novo Nordisk A/S Stable Formulations Of Peptides
AU2006206272A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
CN101460523A (zh) 2006-04-07 2009-06-17 阿道恰公司 双官能化多糖
CA2649109A1 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
FR2902007B1 (fr) 2006-06-09 2012-01-13 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
CN101528749B (zh) 2006-09-07 2013-07-31 工业研究有限公司 核苷磷酸化酶和水解酶的无环胺抑制剂
FR2915683B1 (fr) 2007-05-03 2009-08-07 Flamel Technologies Sa Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
FR2919188B1 (fr) 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
ES2558930T3 (es) 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
PT2597103T (pt) * 2007-11-16 2017-02-08 Novo Nordisk As Composições farmacêuticas contendo insulina e um péptido insulinotrófico
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US20100069292A1 (en) * 2008-09-02 2010-03-18 Biodel, Inc. Insulin with a basal release profile
US20100167984A1 (en) 2008-09-26 2010-07-01 Adocia Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation
FR2940802A1 (fr) * 2008-10-10 2010-07-09 Adocia Complexe entre l'insuline humaine et un polymere amphiphile et utilisation de ce complexe pour la preparation d'une formulation d'insuline humaine rapide.
FR2936800B1 (fr) * 2008-10-06 2010-12-31 Adocia Polysaccharide comportant des groupes fonctionnels carboxyles substitues par un derive d'alcool hydrophobe
US8426382B2 (en) * 2008-10-06 2013-04-23 Adocia Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative
JP5542687B2 (ja) 2008-11-05 2014-07-09 国立大学法人 東京医科歯科大学 ヒアルロン酸誘導体、およびその医薬組成物
CN102216462A (zh) 2008-11-17 2011-10-12 安龙制药公司 用于核酸递送系统的支化阳离子脂质
FR2948573B1 (fr) * 2009-07-31 2011-11-18 Adocia Nouvelle forme d'administration de complexes de proteines osteogeniques
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
WO2010082894A1 (en) * 2009-01-13 2010-07-22 Ge Healthcare Bio-Sciences Ab Precipitation of biomolecules with negatively charged polymers
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) * 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2956116A1 (fr) * 2010-02-09 2011-08-12 Adocia Complexes polysaccharide/bmp-7 solubles a ph physiologique
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
JP5950458B2 (ja) 2010-02-09 2016-07-13 アドシア 少なくとも３価のスペーサーにより保有される少なくとも２つの疎水性基により官能化されたアニオン性多糖類
FR2958647B1 (fr) 2010-04-08 2013-08-23 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent.
EP2388723A1 (en) 2010-05-18 2011-11-23 University College Cork-National University of Ireland, Cork Method of assessing allergic status in a subject
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
WO2012153070A1 (fr) 2011-05-10 2012-11-15 Adocia Oligosaccharides fonctionnalisés
US20120295833A1 (en) 2011-05-10 2012-11-22 Adocia Polysaccharides having an adjustable degree of functionalization
CA2843586A1 (fr) 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
FR2985428B1 (fr) 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
US9198971B2 (en) 2012-01-09 2015-12-01 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
FR2985429B1 (fr) 2012-01-09 2016-07-29 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
US9994615B2 (en) 2012-02-17 2018-06-12 Massachusetts Institute Of Technology Self-regulated peptide hydrogel for insulin delivery
SG11201503598QA (en) 2012-11-13 2015-06-29 Adocia Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂

Also Published As

Publication number Publication date
JP2014521716A (ja) 2014-08-28
RU2578460C2 (ru) 2016-03-27
US20170182131A9 (en) 2017-06-29
CA2843586A1 (fr) 2013-02-14
JP5950477B2 (ja) 2016-07-13
ZA201400773B (en) 2016-11-30
EP2741765B9 (fr) 2016-09-28
IL230611A (en) 2016-10-31
US20130065826A1 (en) 2013-03-14
KR101810055B1 (ko) 2017-12-18
RU2014108829A (ru) 2015-09-20
CN103889442A (zh) 2014-06-25
AU2012293463A1 (en) 2014-03-06
EP2741765B1 (fr) 2016-03-30
EP2741765A1 (fr) 2014-06-18
AU2012293463B2 (en) 2016-08-04
KR20140051384A (ko) 2014-04-30
US20150250858A1 (en) 2015-09-10
US20180311316A1 (en) 2018-11-01
EP3053590A1 (fr) 2016-08-10
CN103889442B (zh) 2016-12-28
MX2014001190A (es) 2014-05-12
US9089476B2 (en) 2015-07-28
DK2741765T3 (en) 2016-06-13
WO2013021143A1 (fr) 2013-02-14
IL230611A0 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
BR112014002986A2 (pt) composição sob a forma de uma solução injetável, e formulação de dose única
SMT201700008B (it) Composizione farmaceutica
DK2694038T3 (da) Farmaceutisk sammensætning
DK2844222T3 (da) Lægemiddelformulering med forsinket udløsning
BR112014012005A2 (pt) composições, métodos, formulação farmacêutica e artigo
DK3192501T3 (da) Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner
BR112013033803A2 (pt) formulação integrada com microagulha, e, método para administrar uma substância
DK3181122T3 (da) Farmaceutisk dasatinib-sammensætning
BR112014003052A2 (pt) composições farmacêuticas
DK3246018T3 (da) Farmaceutisk sammensætning
CO6930367A2 (es) Composiciones farmaceúticas
BR112013014644A2 (pt) composição farmacêutica e complexo
GB201118232D0 (en) Pharmaceutical composition
EE201300005A (et) Ravimkoostis
SMT201600097B (it) Composizione farmaceutica liquida che comprende nitisone
EP2702989A4 (en) STABLE PHARMACEUTICAL COMPOSITION
BR112013000356A2 (pt) formulação farmacêutica injetável de malfalano
HK1189158A1 (en) Pharmaceutical composition
ZA201307216B (en) Novel oxazolidinone derivative and pharmaceutical composition including the same
SMT201600243B (it) Composizioni farmaceutiche comprendenti anakinra senza citrato
BR112015002979A2 (pt) forma cristalina, e, composição farmacêutica
BR112015002646A2 (pt) composto e composição farmacêutica
DK3375468T3 (da) Medicinsk injektor med skraldevirkende stempel
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
FR2958166B1 (fr) Compositions pharmaceutiques fortement dosees en biotine

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B350 Update of information on the portal [chapter 15.35 patent gazette]